Investigation into Nektar Therapeutics Sparks Concerns Among Investors Ahead of Class Action Deadline

Investor Alert on Nektar Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, is currently investigating potential claims against Nektar Therapeutics, Inc. (traded as NKTR on NASDAQ). Investors who acquired securities in Nektar between February 26, 2025, and December 15, 2025, are encouraged to take note of an impending legal deadline: May 5, 2026. This date marks the last opportunity for investors to file for the position of lead plaintiff in a federal securities class action against the company.

The firm highlights the significance of this investigation, particularly focusing on Nektar's alleged violations of federal securities laws. It has come to light that the company and some of its executives may have provided misleading statements regarding its clinical trial results, specifically about the REZOLVE-AA trial.

Clinical Trial Concerns

The REZOLVE-AA trial is pivotal as it examines the efficacy of rezpegaldesleukin, a first-of-its-kind IL-2 pathway agonist touted for its potential in treating autoimmune diseases. However, as detailed in their December 2025 press release, Nektar disclosed that the trial results failed to achieve statistical significance. A critical factor behind this failure was attributed to the inappropriate inclusion of four patients who were not eligible for participation in the study. This revelation resulted in a notable decline in Nektar's stock, with shares dropping $4.14, or 7.77%, leading to a closing price of $49.16 on December 16, 2025.

Legal Implications for Investors

For investors, the implications of these findings could be significant. The court will appoint a lead plaintiff among those with the largest financial interest that is typical and adequate representation for the class. Individuals may either opt to seek this role through counsel or remain passive as class members without impacting their recovery potential.

Faruqi & Faruqi encourages anyone who has suffered losses from their investment in Nektar to reach out and discuss their legal rights, as well as any relevant information regarding the company's conduct. This call for transparency not only pertains to investors but also includes whistleblowers, former employees, and shareholders who may possess crucial information.

How to Get Involved

Those interested in joining this class action or requiring further information can visit Faruqi & Faruqi's dedicated webpage at www.faruqilaw.com/NKTR or directly contact the firm. Partner Josh Wilson is available at their New York office, reachable at 877-247-4292 or 212-983-9330 (Ext. 1310). This outreach is especially vital for those who have faced financial setbacks during this troubling period for Nektar Therapeutics.

Conclusion

As the deadline looms, Nektar Therapeutics investors are strongly advised to be proactive. Engaging with legal professionals can provide clarity on the potential recourse available and the best steps forward. With a history of recovering hundreds of millions for investors since 1995, Faruqi & Faruqi is well-positioned to support affected stakeholders in navigating this challenging situation. For updates on this case and similar occurrences, potential plaintiffs are encouraged to follow the firm on social media platforms including LinkedIn, X, and Facebook for the latest information and announcements.

This financial landscape is fraught with uncertainty, yet engaging with experienced securities litigators may help mitigate loss and pursue rightful claims against corporate conduct.